Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 56 Solid TresibaⓇ performance strengthens basal insulin market share in Japan Japanese basal value market shares TresibaⓇ NPH LevemirⓇ glargine U100 biosimilar glargine U100 - Novo Nordisk Japanese total insulin value market shares Eli Lilly - Sanofi glargine U300 NN Total Basal 80% 70% 60% 50% 40% 30% 20% 10% 0% Nov 2014 Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 value figures changing diabetes® 60% 50% 42% 40% 18% 16% 20% 13% 6% 3% 0% Nov 2017 Nov 2014 Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 value figures 59% 23% 18% Nov 2017 novo nordisk

View entire presentation